Medical Books Online Free

Goy Predicts Strategies for the Future of MCL Treatment Andre H. Goy, MD, predicts the future use of novel combinations for treatment of mantle cell lymphoma.

Rucaparib May Improve PFS in Patients With Ovarian Cancer Jonathan Ledermann, MD, professor of oncology, UCL Cancer Institute, University College London, discusses the results of a subanalysis from the phase III ARIEL trial of rucaparib maintenance treatment for patients with recurrent ovarian carcinoma.

A small molecule protects mitochondrial integrity by inhibiting mTOR activity Mitochondrial damage and ensuring cell death underline many neurodegenerative diseases such as Parkinson’s disease and stroke. Using cellular assays that mimic the activation of mitochondrial apoptosis pathway, we screened out a small molecule that blocks apoptosis by protecting mitochondrial inte...

Factors Impacting Induction Therapy Selection in AML Pinkal Desai, MD, discusses the factors a practicing physician should consider when selecting an appropriate induction therapy for patients with acute myeloid leukemia.

Challenges With Patient Selection for Extended Adjuvant Endocrine Therapy in Breast Cancer Cynthia X. Ma, MD, PhD discusses the challenges with understanding treatment duration for adjuvant endocrine therapy in patients with breast cancer.

The Rationale for Dostarlimab Monotherapy In MSI-H and MSS Endometrial Cancer Ana Oaknin, MD, head of the Gynecologic Tumors Unit, Vall d’Hebron University Hospital, and principal investigator, Gynecological Malignancies Group, explains the rationale for analyzing anti–PD-1 monotherapy with dostarlimab in patients with microsatellite instability–hi...

Response to Checkpoint Inhibition in Urothelial Cancer May Be Affected by Autoimmune Events The development of an immune-related adverse event was associated with improved patient response in an FDA analysis of patients with advanced urothelial cancer treated with a PD-1/PD-L1 inhibitor.

Interpreting the Role of the Ramucirumab Plus Erlotinib Combination in EGFR+ NSCLC Marina C. Garassino, MD, medical consultant, Thoracic Unit, Fondazione IRCCS – Istituto Nazionale dei Tumori, Milan, Italy, discusses the results from the randomized phase III RELAY trial, in which the combination of ramucirumab plus erlotinib was compared to erlotinib plus placebo in patients...

Exploring Durable Responses With Liso-Cel for Relapsed/Refractory CLL Matthew S. Davids, MD, MMSc, discusses the significance of the findings from TRANSCEND CLL 004, a phase I/II trial investigating the CAR T-cell therapy lisocabtagene maraleucel in patients with relapsed or refractory chronic lymphocytic leukemia.

Uncovering a mechanism causing chronic graft-vs-host disease after bone marrow transplant Allogeneic bone marrow transplant (BMT) is an essential treatment to cure patients with blood cancers such as leukemia. In patients who have undergone chemotherapy and radiation, a small number of cancer cells can remain in the bloodstream and allow the malignancy to recur.

Mathematical modeling offers new way to understand variable responses to targeted therapy Cancer therapies that target a specific protein have improved outcomes for patients. However, many patients eventually develop resistance to these targeted therapies and their cancer comes back. It is believed that differences among tumor cells, or heterogeneity, may contribute to this drug resistan...

"The whole science education process is fundamentally flawed" - Craig Mello, Nobel Laureate Nobel Laureate Craig Mello answers the question 'What is the biggest challenge facing young scientists today?' Craig Mello, who received the Nobel Prize for ...